The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man

• Status: Unknown status
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To asses the modulating properties of the cleaved pentapeptide product of GLP-1 amide.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Elahi, Dariush, PhD
• Collaborators: ICON plc; Massachusetts General Hospital; National Institute on Aging (NIA)
• Treatments: Glucagon; Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

• BMI 18.5-25;

• 33-38

Exclusion Criteria:

• T2D

• T1D

• Hypoglycemic agents